Earnings ·
Reports Q3 net loss of $40.1M on $25.3M revenue as CDMO secures new business wins
LFCRLifecore Biomedical, Inc. de
Lifecore Biomedical reported a third-quarter net loss of $40.1 million, or $1.08 per diluted share, compared to a $10.0 million loss in the prior-year period. Revenue declined 18.6% year-over-year to $25.3 million for the quarter and fell 21.8% to $82.7 million for the first nine months of 2026. The company cited lower contract development and manufacturing activity as a driver for the revenue decrease, though operating expenses also dropped significantly. Adjusted EBITDA increased to $4.0 million for the quarter. Management highlighted securing two new technology transfer projects supporting Phase 3 batches and three additional development-phase programs with global pharmaceutical partners. Lifecore Biomedical operates as a fully integrated contract development and manufacturing organization specializing in sterile injectable pharmaceutical products.